Events Search and Views Navigation
Ongoing
2023 Economic Development Week in Maryland
Overview Economic Development Week in Maryland will emphasize the importance of economic development for the State of Maryland. The week is designed to increase understanding of economic development’s contribution to the state’s business climate, job retention and growth, the tax base, and the overall quality of life in Maryland. Recognition Economic development will take center stage in counties, cities, and towns throughout Maryland when proclamations are made heralding the significant projects that have made Maryland a great place to live,...
Find out more »8:00 am
2023 MEDA Fall Conference
The 2023 MEDA Fall Conference will be held October 25, 2023 at the Antrim 1844 in Carroll County, MD and the theme will be Innovations in Manufacturing. To receive a 20% discount on your room reservation for the 2023 MEDA Fall Conference, use the GROUP CODE ‘2310MEDAAT’ when booking on the Antrim 1844 website, select your stay dates as October 24-25, 2023, and be sure to choose the group code option, not the promotional code.
Find out more »9:00 am
Harnessing the Potential of Antibody Drug Conjugates in Oncology
Join us for Harnessing the Potential of Antibody Drug Conjugates (ADCs) in Oncology, on October 25 at Johnson & Johnson Innovation - JLABS @ Washington, DC. We’ll host industry thought leaders as they dig deeper on how ADCs have become a promising cancer treatment and key component in the next generation of oncology therapeutics. Dubbed ‘the next pillar of cancer therapeutics’, ADC technology delivers highly potent treatment agents to specific tumor cells connected to malignancy. From 2019 – 2022, 8...
Find out more »11:00 am
NCI Technology Opportunity Webinar: Anti-EGFR Antibodies for the Treatment of Human Cancers
Register to attend a free NIH webinar. Attendees will learn about new antibodies developed in Dr. David Fitzgerald’s Lab that bind a particular structure on the external domain of epidermal growth factor receptor (EGFR) which is displayed on cancer cells that express high EGFR levels or the variant termed ‘EGFRvIII’. Importantly, these antibodies do not bind normal cells. Therefore, these antibodies are used to deliver toxic payloads (as antibody-drug conjugates - ADCs) to cancer cells without killing normal cells. Additionally,...
Find out more »